AAAS 2009: European-American cooperation on new approaches to HIV treatment
Today at the annual meeting of the American Association for the Advancement of Science (AAAS) in Chicago, Ekaterina Dadachova of the Albert Einstein College of Medicine in New York gave a topical lecture on "Novel approaches to the therapy of infectious diseases", detailing the results of a joint project with scientists at the JRC Institute for Transuranium Elements (ITU) on the use of alpha-immunotherapy as a new option for the treatment of HIV infections.
The hypothesis that antibodies coupled ('labelled') with a radioactive isotope (Bismuth 213) can be used to treat the HIV virus has been successfully tested in a joint project between scientists at JRC-ITU and the Albert Einstein College, with test results provided supporting for the first time that ‘radio-labelled’ antibodies can be used to selectively target and eliminate immunodeficiency virus-infected cells from a patient's body by delivering doses of ionising radiation directly to the infected cells1.
Pre-clinical development testing the efficacy and safety of this novel ‘nuclear medicine’ therapeutic approach are being undertaken in preparation of a Phase I clinical trial in HIV infected patients.
For further information (JRC Press Pack): Alpha-immunotherapy – a new option for the treatment of HIV infections
The JRC collaborates with a number of American scientific and R&D-related organisations. At the AAAS2009 meeting it is presenting its work in a number of symposia on topics including nuclear energy, soil biodiversity, pre-implantation genetic diagnosis and nano-engineered food.
1 Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW, et al. "Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins" PLoS Medicine. 2006, 3(11):2094-103.